EMA says AstraZeneca’s Covid-19 vaccine is safe

Astrageneca Covid-19 vaccine “Safe and effective” and should continue to be used by the European Medicines Agency Announced today After a review Concerns about blood clots.

However, the agency said that of the 25 people who were vaccinated, two were found to be linked to two rare blood clots. It added that warnings should be included with information about the vaccine Providing physicians And patients. Nine of them died.

EU Pharmacovigilance Risk Assessment Committee (PRAC) has been asked to review the safety of the AstraZeneca vaccine. More than 20 European countries including Germany, France, Italy and Spain – Vaccine off The following reports of rare coagulation.

Following the announcement of the EMA, Germany, France, Italy and Spain all reported Will start again Uses the Astragenera vaccine.

On Thursday, EMA Executive Director Emer Cook said in a press briefing that the committee has so far reduced the overall incidence of blood clots among about 20 million people worldwide compared to the general public.

“The committee has reached a clear scientific conclusion,” he said. “This is a safe and effective vaccine.”

But PRAC chairman Sabine Strauss said experts were unable to rule out a link to 18 cases in one condition. Cerebral venous sinus thrombosis (CVST) and its seven cases Distributed intravascular coagulation (DIC), both were seen together with decreased blood platelet count. In CVST, clots can prevent bleeding from the brain, leading to bleeding. DIC is a condition in which clots form in many small blood vessels throughout the body, which can lead to serious organ damage.

The EMA will continue to investigate these incidents and possible links to the vaccine. Cook, however, emphasized that the benefits of the AstraZeneca vaccine, which currently kills thousands of Europeans every week since COVID-19, far outweighs the risk of freezing.

“So what the committee has recommended is to raise awareness,” he said.

Some experts speculated that the incidence of clotting was related to a specific batch of vaccines, but Strauss said the EMA did not support this theory. “The PRAC did not find any evidence regarding a quality or batch issue,” he said.

On Thursday, the White House confirmed the veracity of the report that the Biden administration would send two and a half million doses of the AstraZeneca vaccine to Mexico and one and a half million to Canada. The shots will be taken from existing domestic supplies awaiting FDA approval, which could come just months after the completion of a major U.S. trial of the vaccine.

The steps are followed A request for a dose From Mexico earlier this week. Biden told reporters Thursday that the United States is considering sending any additional doses abroad once the domestic vaccine is exhausted. A top FDA official, Peter Marks, testified in Congress on Wednesday that the vaccine’s immunity proved to be short-lived and that there was some concern about his agency exporting too much in case the U.S. population needed a booster shot.

Others have speculated that the AstraZeneca vaccine will create more problems in the United States, as anti-vaccinators have adopted problems solving it.

“Is there really a filled niche? Would that be credible enough? Or is it going to be another headache? John Moore, a virologist at Well Cornell Medical College in New York who works on vaccine development, told BuzzFeed News earlier this week.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *